Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79788.820.0649%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

BioVie Inc

BIVINASDAQ
Trade with Public
Trade with Public
$2.00
-0.03-1.48%
At close: Sep 4, 5:00 PM EST
$2.00
-0.0003-0.01%
After Hours: Sep 4, 7:58 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

BioVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioVie (BIVI).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOutperform# Analysts2Avg. Consensus PT$4Upside to Avg. PT+100.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 1, 2024ThinkEquityAshok KumarInitiateBuy$3
Nov 30, 2023OppenheimerJay OlsonPT CutOutperform$12→$5

Analyst Ratings News

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

Oppenheimer analyst Jay Olson maintains BioVie (NASDAQ:BIVI) with a Outperform and lowers the price target from $12 to $5.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

Oppenheimer analyst Jay Olson reiterates BioVie (NASDAQ:BIVI) with a Outperform and maintains $12 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved